GlassScriptPhysician profile
Muthusamy Sekar
NPI 1710924535
$5,947.23
in general payments reported to CMS, 2019-2025
30 companies · $677 in 2025
The $677 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $686 · 2021: $782 · 2022: $650 · 2023: $1,156 · 2024: $800 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.87 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $801.52 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $693.38 | 2019-2025 | |
| Pfizer INC. | $623.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $594.77 | 2019-2025 | Farxiga, Brilinta |
| Amgen INC. | $583.40 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $510.78 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $351.10 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $339.86 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Amarin Pharma, INC. | $253.65 | 2019-2022 | |
| Heartflow, INC. | $146.09 | 2023 | Ffrct |
| Abbott Laboratories | $127.89 | 2021-2022 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.18 | 2020-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $78.20 | 2019-2022 | |
| Chiesi USA, INC. | $76.43 | 2019-2025 | Juxtapid, Kengreal |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $72.91 | 2021-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $70.24 | 2022-2025 | |
| Edwards Lifesciences Corporation | $68.14 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $44.89 | 2024 | Bodyguardian, Watchman Flx |
| Angiodynamics, INC. | $39.38 | 2024 | Alphavac |
| Esperion Therapeutics, INC. | $37.41 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $32.95 | 2023-2024 | Opsumit |
| Gilead Sciences, INC. | $32.80 | 2019 | |
| Novo Nordisk INC | $31.41 | 2025 | Ozempic, Wegovy |
| Medtronic Vascular, INC. | $30.29 | 2019 | |
| Abiomed | $29.02 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.18 | 2019 | |
| Vital Connect, INC | $27.05 | 2024 | Vitalpatch Rtm |
| Medtronic, INC. | $22.56 | 2021 | |
| Lundbeck LLC | $17.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muthusamy Sekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.